J45, You may be right (in general) about Reg A+ shares being free-trading. However, that may not be the case when dealing with a reporting company which could have a lot of leeway in how it structures its offering. For example, what if an OTC company issued Reg A+ shares as a preferred class that needed to be held for a predetermined period of time before they could be traded or converted? That would avoid flooding the market and depressing the value of the common shares. The shorts might have a field day knowing that tens of millions of newly issued Reg A+ shares would immediately become free-trading.
I'm sure XERI is carefully weighing their options at this point, which may be why we haven't heard from them in a while -- and perhaps this recent press release was a trial balloon to see how the shorts would react.
Ultimately, if the XERI Reg A+ offering is strategically-crafted and the capital-raising effort is well-executed, the good guys will win (i.e., current shareholders, new Reg A+ investors, and XERI) and the shorts won't have XERI (or its investors) to kick around anymore. (Or at least to this extent.)
News 
Market Data 
Discover 
